MLTX COURT ALERT: MoonLake Immunotherapeutics Investors are Notified the Compay has been Sued for Securities Fraud and are Notified to Contact BFA Law by December 15December 02, 2025 3:33 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 2, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violat ...

PHILADELPHIA, Dec. 2, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a le ...

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit alleges that the defendants made false and misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements in securities class actions, including the largest settlement against a Chinese company and significant recoveries for investors in recent years [4].

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics, Inc. centers on allegations that the company misrepresented the clinical efficacy of its product SLK compared to traditional monoclonal antibodies, particularly BIMZELX, leading to significant investor losses [2][3]. Legal Allegations - The lawsuit claims that MoonLake failed to disclose that SLK and BIMZELX share the same molecular targets (interleukin-17, or IL-17), which undermines the claimed competitive advantage of SLK [3]. - Allegations include that MoonLake misrepresented the Nanobody structure's ability to provide superior clinical efficacy, specifically in treating hidradenitis suppurativa (HS) [3]. - The stock price of MoonLake fell dramatically from $61.99 to $6.24, representing a 90% loss, following the disclosure of these issues [3]. Investor Actions - Hagens Berman is actively advising investors who purchased MLTX shares during the Class Period (March 10, 2024, through September 29, 2025) and suffered substantial losses due to the alleged undisclosed trial flaws [4]. - The deadline for investors to move the Court for appointment as lead plaintiff in the securities class action lawsuit is December 15, 2025 [1][4]. Firm Background - Hagens Berman is a global plaintiffs' rights law firm that has secured over $2.9 billion in settlements for investors in similar cases [4][8].

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15December 01, 2025 3:18 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 1, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the f ...

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Avantor's competitive positioning was weaker than defendants had publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, defendants' representations about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis. DEADLINE: ...

NEW YORK, Dec. 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Accessibility StatementSkip Navigation Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and ou ...

Accessibility StatementSkip Navigation PHILADELPHIA, Dec. 1, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, ...

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational therapeutic sonelokimab [3]. Clinical Trials and Data - The company conducted Phase 3 VELA trials for sonelokimab, which were highly anticipated, and claimed that its "strong clinical data" would lead to higher clinical responses compared to competitors [3][4]. - MoonLake asserted that the Nanobody structure of sonelokimab provided beneficial differences over traditional monoclonal antibody treatments [4]. Allegations and Stock Impact - Allegations state that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. - Following the announcement of disappointing results from the VELA trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [6].

Core Viewpoint - MoonLake Immunotherapeutics has been sued for securities fraud, with allegations that the company misrepresented its clinical data and the efficacy of its investigational drug sonelokimab [1][4][6]. Group 1: Lawsuit Details - A lawsuit has been filed against MoonLake and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][3]. - Investors have until December 15, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its Phase 3 VELA trials for sonelokimab [4]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses and differentiation from competitors [5]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [6]. - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [7].